BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 34653567)

  • 1. Real-world outcomes of two different sensor-augmented insulin pumps with predictive low glucose suspend function in type 1 diabetes patients.
    Moreno-Fernandez J; Beato-Vibora P; Olvera P; Garcia-Seco JA; Gallego-Gamero F; Herrera MT; Muñoz-Rodriguez JR
    Diabetes Res Clin Pract; 2021 Nov; 181():109093. PubMed ID: 34653567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT.
    Benhalima K; van Nes F; Laenen A; Gillard P; Mathieu C
    Diabetologia; 2021 Dec; 64(12):2725-2730. PubMed ID: 34647140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Sensor-Augmented Pump Therapy with Predictive Low-Glucose Suspend Function on Glycemic Control and Patient Satisfaction in Adults and Children with Type 1 Diabetes.
    Beato-Víbora PI; Quirós-López C; Lázaro-Martín L; Martín-Frías M; Barrio-Castellanos R; Gil-Poch E; Arroyo-Díez FJ; Giménez-Álvarez M
    Diabetes Technol Ther; 2018 Nov; 20(11):738-743. PubMed ID: 30256132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
    Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
    Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world outcomes with different technology modalities in type 1 diabetes.
    Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A
    Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1845-1850. PubMed ID: 33838993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
    Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
    Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
    Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
    Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
    Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
    Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Medtronic 780G advanced hybrid closed-loop system achieves and maintains good glycaemic control in type 1 diabetes adults despite previous treatment.
    Quirós C; Alonso-Carril N; Rodríguez-Rodríguez S; Barahona MJ; Orois A; Simó-Servat A; Ramos M; Perea V
    Endocrinol Diabetes Nutr (Engl Ed); 2023 Feb; 70(2):130-135. PubMed ID: 36925230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Improvements in Hypoglycemia in an Insulin-Dependent Cohort With Diabetes Mellitus Pre/Post Tandem Basal-Iq Technology Remote Software Update.
    Pinsker JE; Leas S; Müller L; Habif S
    Endocr Pract; 2020 Jul; 26(7):714-721. PubMed ID: 33471639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real-world study in the UK.
    Choudhary P; de Portu S; Arrieta A; Castañeda J; Campbell FM
    Diabet Med; 2019 Sep; 36(9):1100-1108. PubMed ID: 31134668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of insulin pump therapy with predictive low glucose suspend feature in decreasing hypoglycemia in children with type 1 diabetes mellitus: A systematic review and meta-analysis.
    Alotaibi A; Al Khalifah R; McAssey K
    Pediatr Diabetes; 2020 Nov; 21(7):1256-1267. PubMed ID: 32738022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy.
    Danne T; Kordonouri O; Holder M; Haberland H; Golembowski S; Remus K; Bläsig S; Wadien T; Zierow S; Hartmann R; Thomas A
    Diabetes Technol Ther; 2011 Nov; 13(11):1129-34. PubMed ID: 21827318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sensor-augmented pump therapy (SAPT) with predictive low-glucose management in patients diagnosed with type 1 diabetes mellitus previously treated with SAPT and low glucose suspend.
    Gómez AM; Henao DC; Imitola A; Muñoz OM; Sepúlveda MAR; Kattah L; Guerrero JS; Morros E; Llano JP; Jaramillo MG; León-Vargas F
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Oct; 65(8):451-457. PubMed ID: 29914817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.
    Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R
    Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Low Glucose Suspend Algorithm in Real Life: A Five-Year Follow-Up Retrospective Analysis.
    Tubili C; Pollakova D; Nardone MR; Di Folco U
    J Diabetes Sci Technol; 2021 Nov; 15(6):1303-1307. PubMed ID: 32865016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Efficacy and Safety of Sensor Augmented Insulin Pump Therapy with Low-Glucose Suspend Feature in Patients with Type 1 Diabetes.
    Gómez AM; Marín Carrillo LF; Muñoz Velandia OM; Rondón Sepúlveda MA; Arévalo Correa CM; Mora Garzón E; Cuervo Diaz MC; Henao Carrillo DC
    Diabetes Technol Ther; 2017 Feb; 19(2):109-114. PubMed ID: 28001445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How does a predictive low glucose suspend (PLGS) system tackle pediatric lifespan challenges in diabetes treatment? Real world data analysis.
    Gaweł WB; Deja G; Kamińska H; Tabor A; Skała-Zamorowska E; Jarosz-Chobot P
    Pediatr Diabetes; 2020 Mar; 21(2):280-287. PubMed ID: 31715059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes.
    Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A; Gil-Poch E; Martín-Romo I; Arroyo-Díez FJ
    Diabetes Technol Ther; 2021 Sep; 23(9):609-615. PubMed ID: 33784187
    [No Abstract]   [Full Text] [Related]  

  • 20. The Predictive Low Glucose Management System in Prevention of Clinically Significant Hypoglycemia in Type 1 Diabetes. A Preliminary Study Identifying the Most Common Events Leading Up to Hypoglycemia During Insulin Pump Therapy.
    Thomakos P; Mitrakou A; Kepaptsoglou O; Taraoune I; Barreto C; Zoupas CS
    Exp Clin Endocrinol Diabetes; 2021 May; 129(5):385-389. PubMed ID: 30986882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.